Cynata collaborates on cell therapy for cancer
14 October, 2015Cynata Therapeutics will collaborate with Massachusetts General Hospital on the development of modified mesenchymal stem cells (MSCs) to treat cancer.
Phosphagenics restructure effective immediately
13 October, 2015Drug delivery company Phosphagenics has announced a corporate restructure, effective immediately, following its recent strategic review.
ResMed completes Curative Medical acquisition
12 October, 2015ResMed has completed its acquisition of Curative Medical, a provider of non-invasive ventilation and sleep-disordered breathing medical devices and accessories to the Chinese market.
Paranta Biosciences commences cystic fibrosis trial
06 October, 2015Paranta Biosciences has successfully closed a $7 million financing round, which it will use to fund the development of treatments for inflammatory and fibrotic lung diseases.
A new drug analysis method
02 October, 2015An international team of scientists has been working with a major biopharmaceutical company to investigate new ways to characterise protein formulations.
US$53.9m for Avita to support mass burn injuries
30 September, 2015Avita Medical has been awarded a contract with BARDA, worth up to $53.9 million, which supports late-stage clinical development and procurement of Avita's ReCell autologous cell harvesting device under a mass casualty preparedness program.
The Daraprim price hike and the TPP
28 September, 2015 by Lauren DavisAfter a tumultuous week for Turing Pharmaceuticals — which saw the company raise the price of an essential medicine by over 4000%, only to lower it again in the face of universal criticism — an Australian intellectual property expert warns that similar incidents could occur as a result of the Trans-Pacific Partnership (TPP).
No snow-white apple fairytale for Australia
28 September, 2015 by Graeme O’NeillA Canadian company has begun marketing two non-browning apple varieties that employ CSIRO's patented gene-silencing technology. But in GM-averse Australia, there are no takers — why?
Finalised US distribution deal for IDT cancer drug
24 September, 2015IDT Australia has finalised the appointment of its US partner — a subsidiary of South Australian company Mayne Pharma — for the distribution of its generic temozolomide cancer treatment product.
Brain tumour visualisation drug approved in New Zealand
24 September, 2015Medsafe has approved a drug that helps neurosurgeons to better visualise and remove malignant brain tumours for marketing and distribution in New Zealand.
Australia's 3D-printed ribs
22 September, 2015Australia has contributed to an international collaboration that has led to a world-first in surgery — the implantation of a 3D-printed titanium sternum and rib cage into a Spanish cancer patient.
Capsule endoscopy systems market to hit $399.7m by 2020
17 September, 2015Allied Market Research has claimed that the capsule endoscopy systems market will generate revenue of almost $400 million by 2020, registering a CAGR of 14.8% during 2015–2020.
Orthocell data validated for bone generation
15 September, 2015Shares in Orthocell have jumped over 15%, following the presentation of successful 'cell factory' data at the 34th Annual Meeting of the European Bone and Joint Infection Society.
Improved sterilisation of medical devices
15 September, 2015 by ONBoard SolutionsONBoard Solutions has announced the launch of a product for the room-temperature sterilisation of tissue-engineered and medical device products: REVOX.
Hatchtech head lice drug to be commercialised by Dr Reddy's
15 September, 2015Dr Reddy's Laboratories has signed a commercialisation agreement with Melbourne-based company Hatchtech, the developer of prescription head lice product Xeglyze Lotion.
